Thermo Fisher Scientific’s Greenville facility, a major contract drug manufacturing site, has been flagged for repeated regulatory violations despite its potential for growth in the injectables sector. While the FDA has not taken regulatory action, concerns remain about the plant’s quality control practices, particularly after recent issues with the production of Wegovy and Beyfortus.